Abstract
Background: Histone deacetylases (HDACs) play key roles in many biological phenomena and HDAC inhibition has been proved to be an effective strategy in cancer therapy. Over the last few decades, a plethora of structurally diverse HDAC inhibitors have been reported for a broad range of tumor indications. Among them, macrocyclic HDAC inhibitors, including cyclic peptides, depsipeptides and peptidomimetics, etc., have drawn lots of interests because of the fact that macrocyclic HDAC inhibitors have the potential for member or isoform selective inhibition.
Conclusion: Macrocyclic HDAC inhibitors present an excellent opportunity for the selective modulation of HDAC inhibitors due to their complex recognition cap group moieties. However, compared with the structurally simpler synthetic HDAC inhibitors, efforts to develop macrocyclic HDAC inhibitors have been so far modestly successful with only one compound (romidepsin) approved for the cancer treatment. Development of macrocyclic HDAC inhibitors are hampered by the complex reaction schemes required for their synthesis. We expect that in the near future, more macrocyclic HDAC inhibitors will be identified from natural products; and further modification or SAR studies will be made on these or already known natural macrocyclic HDAC inhibitors. More selective drug-like macrocyclic HDAC inhibitors will be designed and identified after understanding the interactions between the ligand and the HDACs.
Keywords: Histone Deacetylases Inhibitor (HDAC), macrocycle, drug development, drug design, selectivity.
Current Medicinal Chemistry
Title:Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer
Volume: 24 Issue: 37
Author(s): Kai Cheng, Siyu Li and Chenzhong Liao*
Affiliation:
- School of Biological and Medical Engineering, Hefei University of Technology, Hefei 230009,China
Keywords: Histone Deacetylases Inhibitor (HDAC), macrocycle, drug development, drug design, selectivity.
Abstract: Background: Histone deacetylases (HDACs) play key roles in many biological phenomena and HDAC inhibition has been proved to be an effective strategy in cancer therapy. Over the last few decades, a plethora of structurally diverse HDAC inhibitors have been reported for a broad range of tumor indications. Among them, macrocyclic HDAC inhibitors, including cyclic peptides, depsipeptides and peptidomimetics, etc., have drawn lots of interests because of the fact that macrocyclic HDAC inhibitors have the potential for member or isoform selective inhibition.
Conclusion: Macrocyclic HDAC inhibitors present an excellent opportunity for the selective modulation of HDAC inhibitors due to their complex recognition cap group moieties. However, compared with the structurally simpler synthetic HDAC inhibitors, efforts to develop macrocyclic HDAC inhibitors have been so far modestly successful with only one compound (romidepsin) approved for the cancer treatment. Development of macrocyclic HDAC inhibitors are hampered by the complex reaction schemes required for their synthesis. We expect that in the near future, more macrocyclic HDAC inhibitors will be identified from natural products; and further modification or SAR studies will be made on these or already known natural macrocyclic HDAC inhibitors. More selective drug-like macrocyclic HDAC inhibitors will be designed and identified after understanding the interactions between the ligand and the HDACs.
Export Options
About this article
Cite this article as:
Cheng Kai, Li Siyu and Liao Chenzhong*, Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer, Current Medicinal Chemistry 2017; 24 (37) . https://dx.doi.org/10.2174/0929867324666170209105315
DOI https://dx.doi.org/10.2174/0929867324666170209105315 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Bone Marrow Mesenchymal Stem Cells: Agents of Immunomodulation and Neuroprotection
Current Stem Cell Research & Therapy Orally Administrated Small Molecule Drugs with Intestine Targeted Profile: Recent Development and Prospects
Current Medicinal Chemistry The Role of Organic Transporters in Pharmacokinetics and Nephrotoxicity of Newer Antiviral Therapies for HIV and Hepatitis C
Current Drug Metabolism Plant Proteinases and Inhibitors: An Overview of Biological Function and Pharmacological Activity
Current Protein & Peptide Science Cardiac Toxicity of Antineoplastic Anthracyclines
Current Medicinal Chemistry - Anti-Cancer Agents Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin
Mini-Reviews in Medicinal Chemistry The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Docosahexaenoic Acid (DHA) Sensitizes Brain Tumor Cells to Etoposide-Induced Apoptosis
Current Molecular Medicine Opportunities and Challenges of Fluorescent Carbon Dots in Translational Optical Imaging
Current Pharmaceutical Design Detection of Early Cancer: Genetics or Immunology? Serum Autoantibody Profiles as Markers of Malignancy
Anti-Cancer Agents in Medicinal Chemistry Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent
Current Drug Safety The Adenine Nucleotide Translocase 2, a Mitochondrial Target for Anticancer Biotherapy
Current Drug Targets Acrylamide Induced Toxicity and the Propensity of Phytochemicals in Amelioration: A Review
Central Nervous System Agents in Medicinal Chemistry Mouse Models of Multiple Sclerosis: Lost in Translation?
Current Pharmaceutical Design Nutriproteomics – Linking Proteomics Variation with Personalized Nutrition
Current Pharmacogenomics and Personalized Medicine How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets Screening of Potential Plant Compounds as Survivin Inhibitors and its Anti-Cancer Efficacy by Molecular Docking
Current Enzyme Inhibition Tools For Decision-Making In Older Cancer Patients. Role Of The Comprehensive Geriatric Assessment
Anti-Cancer Agents in Medicinal Chemistry